DGAP-News: Biotest AG: Biotest AG signs strategically significant agreement to market human albumin in China
(firmenpresse) - DGAP-News: Biotest AG / Key word(s): Contract
Biotest AG: Biotest AG signs strategically significant agreement to
market human albumin in China
11.12.2012 / 10:52
---------------------------------------------------------------------
/
PRESS RELEASE
Biotest AG signs strategically significant agreement to market human
albumin in China
- Access to fast growing, high-price Chinese albumin market
- Revenue of EUR 20 to EUR 30 million expected in medium term
- Strong sales and distribution partner Wanbang Biopharma, a Fosun Pharma
Group company, as guarantee for success
Dreieich, December 11, 2012. By signing the long-term distribution
agreement Biotest AG emphasized its international growth strategy.
In view of the growing importance of the Chinese market, Biotest has
successfully realised the extension of the marketing authorization for
human albumin. With regard to rising production capacities, we have looked
for a strong sales and distribution partner with whom we can successfully
implement our ambitious growth objectives.
In 2011, 180 tonnes of human albumin were sold in China, more than 40% of
which were imported. The Chinese pharmaceutical market has reported an
annual growth in excess of 20% over the last five years. It is expected
that China will be the world's second-largest pharmaceuticals market* by
2014, with sales of around EUR 85 billion.
Wanbang Biopharma is part of the Fosun Pharmaceuticals Group, and is thus
one of China's largest pharmaceutical companies. Wanbang Biopharma operates
subsidiaries in 28 provinces and employs more than 1,200 marketing and
sales staff. With this newly-launched cooperation venture Biotest has
secured a position on the Chinese albumin market. Should the Chinese market
for plasma products open further, its significance will increase
considerably.
About Fosun Pharma
Fosun Pharma is one of the largest Chinese pharmaceutical companies. With a
broad pharmaceutical product portfolio, fast growing therapeutic areas such
as infectious, liver and mass diseases such as diabetes are served. A
strategic partnership with Sinopharma and the most important pharmacists'
retail chains ensure an extensive distribution network.
* IMS Report, Datamonitor, MOH year book
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of pharmaceutical and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
application of clinical immunology, haematology and intensive medicine. In
its Plasma Protein portfolio Biotest develops and markets immunoglobulins,
coagulation factors and albumins based on human blood plasma. These are
used for diseases of the immune and haematopoietic systems. Biotest alsoresearches into the development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and cancer of plasma cells. Biotest has
more than 1.600 employees worldwide. The preference shares of Biotest AG
are listed in the SDAX on the Frankfurt stock exchange.
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations(at)biotest.de
fax: +49 (0) 6103 801-347
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart
End of Corporate News
---------------------------------------------------------------------
11.12.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations(at)biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
196623 11.12.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 11.12.2012 - 10:52 Uhr
Sprache: Deutsch
News-ID 211387
Anzahl Zeichen: 2003
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 217 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Biotest AG: Biotest AG signs strategically significant agreement to market human albumin in China"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotest AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
